Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Low efficacy prompts treatment cessation in statin-intolerant patients taking pravastatin, fluvastatin

10 Dec 2019
Statin side effects are found to be largely related to patients’ negative expectations.

Despite a relatively low rate of relapse of intolerance among patients taking pravastatin or fluvastatin, many of them have eventually discontinued or switched to other medication, reveals a study. Relapse is independently predicted by chronic kidney disease and history of creatine kinase elevation.

The rate of relapse of intolerance during a median follow-up of 37 months was 10.4 percent among pravastatin users and 18.2 percent among fluvastatin users (p=0.04), but the log-rank test showed no between-group difference in the relapse-free rates (p=0.34).

Cessation rates were 36.5 percent for pravastatin and 42.2 percent for fluvastatin (p=0.30). Reasons for discontinuation were varied, which included low efficacy of the agents.

After adjustment, the following factors were found to be independently associated with relapse: chronic kidney disease (hazard ratio [HR], 1.83; p=0.03) and previous creatine kinase elevation (HR, 3.13; p=0.001). Older age (HR, 1.03; p=0.057) and female sex (HR, 1.70; p=0.059) were associated, albeit nonsignificantly, with relapse.

In this retrospective, propensity score-matched cohort study, the authors screened data sourced from a tertiary university hospital between 2006 and 2015. A total of 8.073 patients were screened, of whom 488 with statin intolerance who received pravastatin or fluvastatin with regular follow-up were enrolled. Of these patients, 384 were included in the analysis after propensity-score matching.

The primary outcome variables were relapse of statin intolerance and cessation (ie, discontinuation or switching to other statins) rate for the two agents.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.